Oasmia Pharma posts positive top-line results for its cancer drug

4 August 2015
2019_biotech_test_vial_discovery_big

Oasmia Pharmaceutical (STO: OSM) on Tuesday reported positive results for its cancer drug Paclical (paclitaxel) following a head-to-head comparison study with Celgene's (Nasdaq: CELG) Abraxane (paclitaxel).

The Sweden-based pharmaceutical company in a statement said the study was conducted in women with metastatic breast cancer. News of the positive trial outcome pushed Oasmia's share  up 5.1% to 18.70 Swedish kronor.

Margareta Eriksson, vice president of clinical development at Oasmia Pharmaceutical, said: "Paclical enables higher doses, shortens infusion time, eliminates the need for pre-medication and improves the safety profile for patients."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology